Press release
Neurofibromatosis Type 2 Market Set for Robust Growth Through 2034, Driven by Promising Pipeline Developments | DelveInsight
Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034
DelveInsight's "Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034 [https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the Neurofibromatosis Type 2 treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and Neurofibromatosis Type 2 market forecasts through 2034, providing crucial insights for stakeholders in the rare disease therapeutic area.
According to DelveInsight's analysis, the Neurofibromatosis Type 2 market is set for steady growth, with a robust compound annual growth rate (CAGR) anticipated from 2024 to 2034. This expansion in the 7MM is further driven by the introduction of innovative therapies such as Brigatinib, REC-2282, and VT3989, as well as growing awareness and diagnosis, and advancements in genetic testing.
Download the Neurofibromatosis Type 2 Market report [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] to understand which factors are driving the therapeutic market.
According to DelveInsight's estimates, there were approximately 17K diagnosed prevalent cases of Neurofibromatosis Type 2 in the 7MM in 2023. Of these, the US accounted for approximately 62% of the cases, EU4 and the UK accounted for around 33%, followed by Japan, which represented nearly 5%. Furthermore, in the US specifically, the total diagnosed prevalent cases of Neurofibromatosis Type 2 were approximately 10.6 thousand in 2023, with this number anticipated to rise during the forecast period (2024-2034).
Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of Neurofibromatosis Type 2, with approximately 1,400 cases in 2023, followed by the UK with approximately 1,200 cases, and France with nearly 1,100 cases. Furthermore, among the age-specific diagnosed prevalent cases in the US, the highest cases were observed in adults with approximately 9K as compared to Children and Adolescents with nearly 1,700.
Discover evolving trends in the Neurofibromatosis Type 2 patient pool forecasts [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Currently, there are no FDA-approved therapies specifically for Neurofibromatosis Type 2, representing a major unmet need in the market. The Neurofibromatosis Type 2 treatment aims to alleviate disabling symptoms and enhance overall survival, with surgical resection remaining the primary intervention for managing growing tumors, though it poses significant morbidity risks. Radiotherapy is typically avoided due to concerns regarding secondary malignancies and the potential for malignant transformation.
According to the DelveInsight report, the Neurofibromatosis Type 2 therapies pipeline shows promising developments with several novel treatments in clinical development. REC-2282 by Recursion Pharmaceuticals is a CNS-penetrant, orally bioavailable small-molecule pan-HDAC inhibitor in development for Neurofibromatosis Type 2-mutated meningiomas. Demonstrating good tolerability, including long-term dosing, it potentially offers reduced cardiac toxicity compared to existing HDAC inhibitors. In June 2022, the initiation of the Phase II/III POPLAR-Neurofibromatosis Type 2 clinical trial was announced, evaluating REC-2282 for progressive Neurofibromatosis Type 2-mutated meningiomas. The FDA granted Fast Track designation for REC-2282 in October 2021, which also holds Orphan Drug designations from both the FDA and the European Commission.
VT3989 by Vivace Therapeutics has demonstrated efficacy as a monotherapy against tumors reliant on Hippo pathway dysfunction and shows promise in combination with other anti-cancer therapies across various tumor types. In April 2023, Vivace Therapeutics presented initial clinical data at the American Association for Cancer Research (AACR) Annual Meeting, with results from a Phase 1 study of this first-in-class TEAD autopalmitoylation inhibitor indicating that VT3989 was well tolerated, yielding durable antitumor responses in patients with advanced malignant mesothelioma and tumors associated with Neurofibromatosis Type 2 mutations.
Discover recent advancements in the Neurofibromatosis Type 2 landscape @ Neurofibromatosis Type 2 Recent Developments [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Neurofibromatosis Type 2 treatment market faces significant challenges, with a major market barrier being the limited patient population due to its rarity, which reduces the commercial incentive for pharmaceutical companies to invest in large-scale drug development. This restricts the availability of funding and resources, hindering progress in discovering and advancing novel therapies. Additionally, advances in understanding the molecular biology of Neurofibromatosis Type 2 have illuminated its etiology, revealing several potential molecular targets for therapeutic intervention, particularly concerning central nervous system lesions.
Major players, including Recursion Pharmaceuticals, Delta Pharmaceuticals Co. Ltd., Shandong Simcere-Medgenn Bio-pharmaceutical Co. Ltd., Novartis Pharmaceuticals, Genentech Inc., GlaxoSmithKline, and AstraZeneca, are all advancing a variety of therapies through robust R&D and strategic collaborations, making the Neurofibromatosis Type 2 therapeutic landscape competitive.
Looking ahead, the Neurofibromatosis Type 2 market is expected to witness continued innovation. Emerging biologically targeted therapies show promise, focusing on the dysfunction of the merlin protein, which is crucial in regulating key intracellular signaling pathways, including VEGF, MEK1/2, and mTOR. As research continues and awareness grows, the Neurofibromatosis Type 2 market is poised for remarkable expansion and therapeutic innovation through 2034, addressing the significant unmet medical needs in this rare genetic disorder.
Table of Contents
1. Key Insights
2. Executive Summary of Neurofibromatosis Type 2
3. Competitive Intelligence Analysis for Neurofibromatosis Type 2
4. Neurofibromatosis Type 2 Market Overview at a Glance
5. Neurofibromatosis Type 2: Disease Background and Overview
6. Neurofibromatosis Type 2 Patient Journey
7. Neurofibromatosis Type 2 Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Neurofibromatosis Type 2 Unmet Needs
10. Key Endpoints of Neurofibromatosis Type 2 Treatment
11. Neurofibromatosis Type 2 Marketed Products
12. Neurofibromatosis Type 2 Emerging Therapies
13. Neurofibromatosis Type 2: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neurofibromatosis Type 2
17. KOL Views
18. Neurofibromatosis Type 2 Market Drivers
19. Neurofibromatosis Type 2 Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Neurofibromatosis Type 2 Pipeline Insight [https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Neurofibromatosis Type 2 pipeline insight provides comprehensive insights about the Neurofibromatosis Type 2 pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Neurofibromatosis Type 2 companies, including AstraZeneca, Recursion Pharmaceuticals, Betta Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Genentech, and Takeda, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurofibromatosis-type-2-market-set-for-robust-growth-through-2034-driven-by-promising-pipeline-developments-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 2 Market Set for Robust Growth Through 2034, Driven by Promising Pipeline Developments | DelveInsight here
News-ID: 4107190 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Neurofibromatosis
Neurofibromatosis Type 2 (NF2) Market Massive Growth opportunity Ahead
Introduction
Neurofibromatosis Type 2 (NF2) is a rare genetic disorder caused by mutations in the NF2 gene, leading to the development of benign tumours on the brain, spinal cord, and peripheral nerves. The hallmark of NF2 is bilateral vestibular schwannomas, which can cause hearing loss, balance issues, and neurological complications. While the condition is non-malignant, its progressive nature and impact on quality of life make it a serious healthcare challenge.
Currently, there…
Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Repor …
DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurofibromatosis…
Neurofibromatosis Type-1 Market Is Booming Worldwide - AstraZeneca, GlaxoSmithKl …
Neurofibromatosis Type-1 Market Insights
The Neurofibromatosis Type-1 Market is projected to reach USD 2.4 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).
Coherent Market Insights has published a new comprehensive analysis on the Neurofibromatosis Type-1 Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market size, revenue forecasts, CAGR, adoption trends, and regulatory drivers. Backed by clinical evidence…
Neurofibromatosis Treatment Drugs Market Future Business Opportunities 2025-2032 …
The latest report, titled "Neurofibromatosis Treatment Drugs Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", published by Coherent Market Insights, offers an in-depth analysis of the industry, covering key market dynamics, competitive landscape, regional insights, and recent developments. The Neurofibromatosis Treatment Drugs Market has experienced substantial growth in recent years, driven by increasing product demand, a growing customer base, and ongoing technological advancements. This report provides a detailed…
Neurofibromatosis Treatment Market Size, Industry And Forecast To 2033
The new report published by The Business Research Company, titled Neurofibromatosis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $11.41 billion in 2023…
Neurofibromatosis Treatment Market to Set Phenomenal Growth by 2023
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
